Biperiden

Biperiden has been studied in 1 paper since 2025: 1 trial in people; 1 in the past year. The newest paper, Dec 25, 2025: “Assessing biomarkers for predicting Alzheimer's disease in TBI patients: A subanalysis of the double‐blinded, phase III randomized clinical trial with biperiden”.

Intervention

1 paper studies it2 more mention it1 findingUpdated

PubChemChEBI

See all 3 papers on biperiden

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“While biperiden treatment did not significantly alter biomarker levels across the overall cohort”
Assessing biomarkers for predicting Alzheimer's disease in TBI patients: A subanalysis of the double‐blinded, phase III randomized clinical trial with biperidenAAIC 2025 abstract2025doi:10.1002/alz70856_103686
Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Human trial1

Studies in people

1 study gave biperiden to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on GFAP

Randomized trial123 peopleBothAcute phase post-TBIAAIC 2025 abstract, Dec 25, 2025

What did studies of biperiden find?

1

Studies of biperiden measured one outcome, GFAP.

GFAP

no changein humans1

1 study
  1. Biperiden showed no clear effect on GFAP in humans (acute phase post-TBI).

    “While biperiden treatment did not significantly alter biomarker levels across the overall cohort”

    Human trialacute phase post-TBIserum

    Assessing biomarkers for predicting Alzheimer's disease in TBI patients: A subanalysis of the double‐blinded, phase III randomized clinical trial with biperiden

    AAIC 2025 abstract

More on GFAP

Latest

Dec 2025: 1Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months